A modified BCG with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice

  1. Moagi Tube Shaku
  2. Peter K Um
  3. Karl L Ocius
  4. Alexis J Apostolos
  5. Marcos M Pires
  6. William R Bishai
  7. Bavesh D Kana  Is a corresponding author
  1. University of the Witwatersrand, South Africa
  2. Johns Hopkins University, United States
  3. University of Virginia, United States

Abstract

Mechanisms by which Mycobacterium tuberculosis (Mtb) evades pathogen recognition receptor activation during infection may offer insights for the development of improved tuberculosis (TB) vaccines. Whilst Mtb elicits NOD-2 activation through host recognition of its peptidoglycan-derived muramyl dipeptide (MDP), it masks the endogenous NOD-1 ligand through amidation of glutamate at the second position in peptidoglycan side-chains. As the current BCG vaccine is derived from pathogenic mycobacteria, a similar situation prevails. To alleviate this masking ability and to potentially improve efficacy of the BCG vaccine, we used CRISPRi to inhibit expression of the essential enzyme pair, MurT-GatD, implicated in amidation of peptidoglycan side-chains. We demonstrate that depletion of these enzymes results in reduced growth, cell wall defects, increased susceptibility to antibiotics, altered spatial localization of new peptidoglycan and increased NOD-1 expression in macrophages. In cell culture experiments, training of a human monocyte cell line with this recombinant BCG yielded improved control of Mtb growth. In the murine model of TB infection, we demonstrate that depletion of MurT-GatD in BCG, which is expected to unmask the D-glutamate diaminopimelate (iE-DAP) NOD-1 ligand, yields superior prevention of TB disease compared to the standard BCG vaccine. In vitro and in vivo experiments in this study demonstrate the feasibility of gene regulation platforms such as CRISPRi to alter antigen presentation in BCG in a bespoke manner that tunes immunity towards more effective protection against TB disease.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 1, 2, 3, and 4. Source data files are also provided for the supplementary information.

Article and author information

Author details

  1. Moagi Tube Shaku

    DST/NRF Centre of Excellence for Biomedical TB Research, University of the Witwatersrand, Johannesburg, South Africa
    Competing interests
    No competing interests declared.
  2. Peter K Um

    Department of Medicine, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8215-9493
  3. Karl L Ocius

    Department of Chemistry, University of Virginia, Charlottesville, United States
    Competing interests
    No competing interests declared.
  4. Alexis J Apostolos

    Department of Chemistry, University of Virginia, Charlottesville, United States
    Competing interests
    No competing interests declared.
  5. Marcos M Pires

    Department of Chemistry, University of Virginia, Charlottesville, United States
    Competing interests
    No competing interests declared.
  6. William R Bishai

    Department of Medicine, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8734-4118
  7. Bavesh D Kana

    DST/NRF Centre of Excellence for Biomedical TB Research, University of the Witwatersrand, Johannesburg, South Africa
    For correspondence
    bavesh.kana@nhls.ac.za
    Competing interests
    Bavesh D Kana, Senior editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9713-3480

Funding

Howard Hughes Medical Institute (HHMI000)

  • Bavesh D Kana

South African Medical Research Council

  • Bavesh D Kana

South African Medical Research Council

  • Moagi Tube Shaku

National Research Foundation

  • Bavesh D Kana

National institutes of health (NIH AI 155346)

  • William R Bishai

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were approved by the Johns Hopkins University Animal Care and Use Committee (Protocol number: MO20M20).

Copyright

© 2024, Shaku et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,156
    views
  • 223
    downloads
  • 5
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Moagi Tube Shaku
  2. Peter K Um
  3. Karl L Ocius
  4. Alexis J Apostolos
  5. Marcos M Pires
  6. William R Bishai
  7. Bavesh D Kana
(2024)
A modified BCG with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice
eLife 13:e89157.
https://doi.org/10.7554/eLife.89157

Share this article

https://doi.org/10.7554/eLife.89157

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Stephanie M Stuteley, Ghader Bashiri
    Insight

    In the bacterium M. smegmatis, an enzyme called MftG allows the cofactor mycofactocin to transfer electrons released during ethanol metabolism to the electron transport chain.

    1. Microbiology and Infectious Disease
    Chenghao Jia, Chenghu Huang ... Min Yue
    Research Article

    Bacterial regional demonstration after global dissemination is an essential pathway for selecting distinct finesses. However, the evolution of the resistome during the transition to endemicity remains unaddressed. Using the most comprehensive whole-genome sequencing dataset of Salmonella enterica serovar Gallinarum (S. Gallinarum) collected from 15 countries, including 45 newly recovered samples from two related local regions, we established the relationship among avian-specific pathogen genetic profiles and localization patterns. Initially, we revealed the international transmission and evolutionary history of S. Gallinarum to recent endemicity through phylogenetic analysis conducted using a spatiotemporal Bayesian framework. Our findings indicate that the independent acquisition of the resistome via the mobilome, primarily through plasmids and transposons, shapes a unique antimicrobial resistance profile among different lineages. Notably, the mobilome-resistome combination among distinct lineages exhibits a geographical-specific manner, further supporting a localized endemic mobilome-driven process. Collectively, this study elucidates resistome adaptation in the endemic transition of an avian-specific pathogen, likely driven by the localized farming style, and provides valuable insights for targeted interventions.